Table 1 Baseline characteristics of the IPF patients
Characteristic | value |
|---|---|
Number of participants (n) | 9 |
Age (years) | 67 (IQR 60, 77) |
Male gender total [n, (%)] | 8 (88.8%) |
IPF duration at time of first RP (months) | 9.0 (IQR 8, 28) |
BMI (kg/m2) | 24.9 (IQR 24.0, 29.8) |
Current smoker [n, (%)] | 0 (0%) |
Former smoker [n, (%)] | 8 (88.9%) |
Never smoker [n, (%)] | 1 (11.1%) |
Pack years (years) | 20 (IQR 9.3, 30) |
FEV1/FVC (% predicted) | 88 (IQR 86, 90) |
FVC (L) | 2.59 (IQR 2.2, 3.1) |
FVC (% predicted) | 58 (IQR 56, 77) |
DLCO corr (% predicted) | 41 (IQR 35, 43) |
GAP-Score (points) | 4.0 (IQR 3, 5) |
Presence of OSA with AHI > 5/h [n, (%)] | 6 (75.0%) |
Presence of OSA with AHI > 15/h [n, (%)] | 2 (22.2%) |
CPAP treatment (n) | 1 (11.1%) |
Antifibrotic treatment [n, (%)] | 8 (88.9%) |
Pirfenidone [n, (%)] | 5 (62.5%) |
Nintedanib [n, (%)] | 3 (37.5%) |
Duration of antifibrotic treatment (months) | 7 (IQR 3.5, 10.8) |
Long term oxygen therapy [n, (%)] | 3 (33.3%) |